Literature DB >> 7754673

Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213.

C N dos Santos1, P R Post, R Carvalho, I I Ferreira, C M Rice, R Galler.   

Abstract

The complete nucleotide sequence of the genome from two yellow fever (YF) virus vaccine strains, 17DD and 17D-213, has been determined. Comparison of these sequences with those of other YF viruses including the parental virulent Asibi strain allowed the identification of 48 nucleotide sequence differences which are common to all 17D substrains. This is a significant reduction from the 67 nucleotide changes originally reported as being 17D-specific and potentially related to viral attenuation. The 48 changes are scattered throughout the genome, 26 of which are silent and 22 led to amino acid substitutions. These 22 changes are bona fide candidates to test by mutating the infectious YF cDNA to investigate their role in viral attenuation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7754673     DOI: 10.1016/0168-1702(94)00076-o

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  18 in total

Review 1.  Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.

Authors:  Gavin C Bowick; Alexander J McAuley
Journal:  Bioeng Bugs       Date:  2011-05-01

2.  Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Authors:  Monica A McArthur; Miguel T Suderman; John-Paul Mutebi; Shu-Yuan Xiao; Alan D T Barrett
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  RNA interference inhibits yellow fever virus replication in vitro and in vivo.

Authors:  Carolina C Pacca; Adriana A Severino; Adriano Mondini; Paula Rahal; Solange G P D'avila; José Antonio Cordeiro; Mara Correa Lelles Nogueira; Roberta V M Bronzoni; Maurício L Nogueira
Journal:  Virus Genes       Date:  2009-01-25       Impact factor: 2.332

4.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

Review 5.  Yellow fever: a reemerging threat.

Authors:  Christina L Gardner; Kate D Ryman
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

6.  E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

Review 7.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

8.  The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon.

Authors:  Maudry Laurent-Rolle; Juliet Morrison; Ricardo Rajsbaum; Jesica M Levingston Macleod; Giuseppe Pisanelli; Alissa Pham; Juan Ayllon; Lisa Miorin; Carles Martinez; Benjamin R tenOever; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2014-09-10       Impact factor: 21.023

9.  Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Authors:  Anabelle Lefeuvre; Philippe Marianneau; Vincent Deubel
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

10.  17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.

Authors:  Ana Carolina Campi-Azevedo; Luiza Pacheco de Araújo-Porto; Maria Luiza-Silva; Maurício Azevedo Batista; Marina Angela Martins; Renato Sathler-Avelar; Denise da Silveira-Lemos; Luiz Antonio Bastos Camacho; Reinaldo de Menezes Martins; Maria de Lourdes de Sousa Maia; Roberto Henrique Guedes Farias; Marcos da Silva Freire; Ricardo Galler; Akira Homma; José Geraldo Leite Ribeiro; Jandira Aparecida Campos Lemos; Maria Auxiliadora-Martins; Iramaya Rodrigues Caldas; Silvana Maria Elói-Santos; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.